Protembis GmbH

Protembis GmbH is a German medical technology company dedicated to developing innovative solutions for protecting patients from brain injuries during left-sided heart procedures. Their flagship product, the ProtEmbo® Cerebral Protection System, is a catheter-based filter device designed to deflect embolic material away from the brain during transcatheter aortic valve replacement (TAVR) procedures. The ProtEmbo® system is currently undergoing clinical investigations and is not yet approved for commercial use.

Protembis is driven by a strong commitment to patient safety and improving the quality of life for individuals undergoing heart procedures. They are pursuing a rigorous clinical development strategy, including FDA-approved IDE studies, to validate the effectiveness and safety of their ProtEmbo® System. They are also actively expanding their presence in the US market through collaborations with the German Accelerator Life Sciences program.

Protembis GmbH is a medical device company dedicated to developing and commercializing innovative solutions for protecting patients from brain injury during left-sided heart procedures, particularly transcatheter aortic valve replacement (TAVR). Their mission is to improve patient quality of life and reduce healthcare costs associated with brain injury by providing a simple, reliable, and effective cerebral embolic protection system, known as the ProtEmbo®.

Protembis promotes a culture focused on innovation, patient-centricity, and collaboration. They value the experience, talent, and drive of their team members, who are committed to bringing Class III medical devices from idea to clinical use. They are passionate about improving patient quality of life and reducing healthcare costs, and their collaborative approach is reflected in their partnerships with universities, investors, and other medical device companies.